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ARTICLE OPEN
Seeing other perspectives: evaluating the use of virtual
and augmented reality to simulate visual impairments
(OpenVisSim)
Pete R. Jones 1,2,3✉, Tamás Somoskeöy 1, Hugo Chow-Wing-Bom 2,3 and David P. Crabb 1
Simulations of visual impairment are used to educate and inform the public. However, evidence regarding their accuracy remains
lacking. Here we evaluated the effectiveness of modern digital technologies to simulate the everyday difficulties caused by
glaucoma. 23 normally sighted adults performed two everyday tasks that glaucoma patients often report difficulties with: a visual
search task in which participants attempted to locate a mobile phone in virtual domestic environments (virtual reality (VR)), and a
visual mobility task in which participants navigated a physical, room-scale environment, while impairments were overlaid using
augmented reality (AR). On some trials, a gaze-contingent simulated scotoma—generated using perimetric data from a real patient
with advanced glaucoma—was presented in either the superior or inferior hemifield. The main outcome measure was task
completion time. Eye and head movements were also tracked and used to assess individual differences in looking behaviors. The
results showed that the simulated impairments substantially impaired performance in both the VR (visual search) and AR (visual
mobility) tasks (both P < 0.001). Furthermore, and in line with previous patient data: impairments were greatest when the simulated
Visual Field Loss (VFL) was inferior versus superior (P < 0.001), participants made more eye and head movements in the inferior VFL
condition (P < 0.001), and participants rated the inferior VFL condition as more difficult (P < 0.001). Notably, the difference in
performance between the inferior and superior conditions was almost as great as the difference between a superior VFL and no
impairment at all (VR: 71%; AR: 70%). We conclude that modern digital simulators are able to replicate and objectively quantify
some of the key everyday difficulties associated with visual impairments. Advantages, limitations, and possible applications of
current technologies are discussed. Instructions are also given for how to freely obtain the software described (OpenVisSim).
npj Digital Medicine            (2020) 3:32 ; https://doi.org/10.1038/s41746-020-0242-6
INTRODUCTION
Over 100 million people worldwide live with a chronic visual
impairment (VI). The most common causes are glaucoma, age-
related macular degeneration (AMD), and cataracts1. Unlike with
long- or short-sightedness, the effects of VIs can be complex and
highly heterogenous. Often, only a certain part of the visual-field is
affected (e.g., predominantly peripheral vision in glaucoma, or
predominantly central vision in AMD), and information in these
regions is often not eliminated completely, but rather degraded in
a variety of subtle ways: becoming blurry, faded, jumbled, or
distorted2. Furthermore, symptoms may also vary markedly across
individuals, eyes, and over time, with the sorts of visual symptoms
a patient reports commensurate with the severity of damage.
Given the prevalence and complexity of VIs, simulations are
often used to help communicate the day-to-day challenges that
visually impaired individuals may experience. In medicine,
simulations are used to educate the public, or to inform caregivers
about a particular individual’s needs. In vision science, simulations
are used to study the effects of VIs on tasks of daily living3. In
health economics, an effective VI simulator has long been sought
after as a way of informing health panels assessing the value-for-
money of novel sight-loss treatments4. While in engineering, an
effective simulator would aid in the design and assessment of
more accessible products5 and built environments6.
Historically, VI simulators have consisted of either a static image
or a pair of spectacles (‘SimSpecs), onto which a ‘black blob’ is
superimposed to occlude a particular region of the visual field (see
Fig. 1a). Such depictions are generally regarded as crude and
unrealistic by patients, however2,7. They do not adequately reflect
the range of symptoms that patients experience, and they allow
the user to simply move their eyes to ‘look past’ the impairment. A
more recent approach has been to apply a region of opacity to a
contact lens8. Unlike SimSpecs, this allows the impairment to
move with the eye (i.e., and so remains invariant on the retina, as
with true VIs). However, the symptoms elicited by contact lenses
also remain unrepresentative of real VIs: even a small region of
opacity results in a diffuse shadow cast over the whole retina,
rather than the localized degradations of form or spatial detail
typically reported by patients4.
Recently, we described a more sophisticated simulator9 in
which a Head Mounted Display (HMD) with integrated eye-
tracking is used to perform gaze-contingent digital manipulations
in virtual or augmented reality (VR/AR). The requisite hardware is
widely commercially available, and, by using software that we
have made freely available online (OpenVisSim), multiple different
symptoms can be simulated simultaneously and in real-time (Fig.
1b; see Methods for how to obtain the software). Furthermore,
each symptom can be parametrically manipulated, based on
empirical eye-test data, and symptoms can be applied indepen-
dently to each eye (Fig. 1c). While wearing the HMD, the user is
free to walk around their environment, and to move their head
and eyes. This means that users are able to perform the sorts of
1Division of Optometry and Visual Science, School of Health Science, Northampton Square, City, University of London, London EC1V 0HB, UK. 2Institute of Ophthalmology,
University College London (UCL), 11-43 Bath Street, London EC1V 9EL, UK. 3NIHR Moorfields Biomedical Research Centre, London EC1V 2PD, UK. ✉email: peter.jones@city.ac.uk
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common, everyday actions that matter to patients, such as
reading a newspaper or making a cup of tea.
Even the most sophisticated simulator will never be able to
recreate exactly ‘what it is like’ to see through somebody else’s
eyes. However, the question for the present work is whether these
latest digital, gaze-contingent HMD simulations are sufficiently
realistic to be of practical utility. We operationalized this question
by asking whether OpenVisSim is capable of reproducing, in
normally-sighted observers, the same basic patterns of difficulties
that real glaucoma patients exhibit when faced with everyday
tasks of daily living.
We focused on glaucoma for this initial assessment of the
technology because it is one of the most common causes of
irreversible sight loss worldwide1, but also because it is one of the
most widely misunderstood10–14. It can be particularly hard for
somebody with normal vision to imagine what a loss of peripheral
vision is like, or why it is that an individual with healthy (‘20–20’)
central vision is nonetheless more likely to fall15, to be involved in
a car accident16, or to live a more sedentary and restricted life17. A
further advantage is that glaucoma has been widely studied, and
the difficulties faced by glaucoma patients are well characterized.
In brief, individuals with glaucoma often report particular difficulty
locating objects in cluttered visual scenes18, and also exhibit
reduced mobility17 and increased risk of falls15. Furthermore, these
difficulties tend to be most pronounced when the loss occurs in
the inferior visual field, compared to when the loss of vision occurs
above the midline19,20. It has also been shown that individuals
with glaucoma tend to make more eye- and head- movements, to
compensate for their restricted field of view21–23.
To examine whether these phenomena could be elicited by a
simulated impairment, we asked normally-sighted adults to
perform two everyday tasks. One was an Object Search task, in
which they attempted to locate a smartphone in a virtual house
(Fig. 2). The other was a Visual Mobility task, in which the
participant attempted to navigate a real physical environment,
using AR (Fig. 3). Both were performed with and without
simulated visual field loss (VFL). The simulated vision loss was
based on perimetric data from a real patient with glaucoma, and
was located in either the inferior or superior hemifield. If the
simulator is capable of functionally approximating the true
glaucoma patients experience, then both forms of VFL should
elevate search times, but the effect should be greatest when the
VFL was inferior. To examine whether the VI also caused changes
in looking behaviors, eye- and head- movements were also
recorded using the near-infrared and gyroscopic sensors con-
tained within the HMD.
RESULTS
Performance: VR visual search
Compared to No VFL (Visual Field Loss), median search times were
74% slower in the Superior VFL condition (+3.7 secs; Wilcoxon
signed-rank test: z=−3.82, P < 0.001), and 125% slower in the
Inferior VFL condition (+ 6.3 secs; z=−3.82, P < 0.001). Search
Fig. 1 Simulations of sight loss. a Example of a conventional depiction of peripheral vision loss (e.g., glaucoma) using a crude method of
occlusion. Such simulations are typically regarded as unrealistic by patients2; b Peripheral vision loss as simulated in OpenVisSim. Clinical
visual field data from static automated perimetry is used to construct a gaze-contingent field map, which specifies the amount of blur to apply
to each pixel. See Methods for details; c Examples of other potential image manipulations supported by OpenVisSim (not evaluated in the
present paper). Additional visual disturbances, such as nystagmus, non-stationary warping, dynamic noise, and binocular misalignment
(strabismus), are also supported, but cannot be easily illustrated using individual static images. For a video demonstrating many of these
effects, see Supplementary Video 1.
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times were significantly slower for Inferior VFL than Superior VFL
(z=−3.02, P= 0.003; Fig. 4a), and the difference (+ 2.6 secs) was
70% as great as the difference between the Superior condition
and No VFL (+ 3.7 secs). Participants also made more head
movements (z=−2.37, P= 0.017) and more eye movements in
the Inferior VFL condition (z=−3.09, P= 0.002) versus the
Superior condition (Fig. 4b), and also rated the Inferior VFL
condition as more difficult (z=−2.29, P= 0.022; Fig. 4c). The
differences in search time observed between the three conditions
occurred consistently throughout the testing session, with no
compelling evidence of learning or fatigue (Fig. 4d).
Individual variability
There was considerable individual variability in how well
participants coped with the presence of simulated VFL. Thus,
while all participants were slower in the two VFL loss conditions
than in the No VFL condition, mean response times increased by
between 7 and 134% for the Superior impairment (mean [SD]:
80% [41%]), and by 52–220% for the Inferior impairment (mean
[SD]: 125% [46%]).
These individual differences in performance were associated
with systematic differences in gaze behavior. Thus, as shown in
Fig. 2 VR search task methods. a Hardware: The Fove0 VR headset with integrated eye tracking, which was worn throughout. b Task:
Example screenshots from the VR simulator, while performing the Object Search task. Virtual rooms were configured into a complete
‘suburban style’ house. Depending on the player location, it was often possible to see into other rooms, connecting hallways, etc. For added
realism the outdoor scenes were also rendered and could be seen from those rooms with external windows (see top-right panel). On each
trial, the target phone (highlighted in the bottom-left panel) was placed at a random location. Examples of the superior and inferior VFL (right-
eye only) are depicted in the bottom-middle and bottom-right panels, respectively (NB: the red crosshair indicates current their point of
fixation and was not visible to participants). c The empirical perimetric data used to generate the simulated VFL. The superior field-loss
measurements were made using Static Automated Perimetry, using a single observer with an established diagnosis of glaucoma (see
Methods). The inferior loss is the exact mirror inverse of the superior. See Supplementary Video 2 for an example trial.
Fig. 3 AR Visual Mobility task methods. a Hardware: The modified HTC Vive headset, with ZEDmini stereoscopic cameras and integrated
Tobii eye-tracking. b Task: Screenshots from four simultaneous camera feeds, recorded during a typical trial of the Visual Mobility task. The
participant’s task was to trace an approximately ‘s’ shaped route (green line) from the start point [S] to the finish point [F]. The configuration of
the blue partitions, and the exact location of the two foam obstacles (shown in bottom left panel), was varied randomly between trials. An
experimenter followed the observer at a safe-distance in case of any trips or accidents. See Bainbridge et al.59 for further details. c The
simulated VFL conditions were the same as in the main experiment (Fig. 2). See Supplementary Video 3 for an example trial.
P.R. Jones et al.
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Fig. 5, participants tended to fixate around the midline in the No
VFL condition, but fixated consistently higher in the Inferior VFL
condition (z= 3.82, P < 0.001), and consistently lower in the
Superior VFL condition (z=−3.70, P < 0.001; Fig. 5a). This pattern
was observed in all 19 individuals (Fig. 5b). However, those
observers who modified their gaze least, and continued to fixate
more centrally in all conditions, performed faster in the
impairment conditions (Quadratic regression; F(2,54)= 12.01, P <
0.001, R2= 0.31; Fig. 5c). This suggests that observers who utilized
more adaptive viewing strategies were better-able to cope with
the exact same vision loss.
Performance: AR visual mobility
The pattern of results in the AR mobility task was the same as in
the main VR visual search task. Participants were slower to
complete the maze when vision was impaired, but were
particularly slow when the impairment was Inferior (Fig. 6).
Compared to the No VFL condition, participants were 13%/52%
(photopic/mesopic) slower in the Superior VFL condition, and
23%/95% (photopic/mesopic) slower in the Inferior VFL condition.
Under photopic lighting, the difference between the Superior and
Inferior conditions (+3.0 s) was 71% as great as the difference
between the Superior VFL condition and No VFL (+4.3 s). Under
mesopic lighting, the difference between the Superior VFL and
Inferior VFL conditions (+13.0 s) was 76% as great as the
difference between the Superior VFL condition and No VFL
(+16.8 s). As in the main VR experiment, however, there was
substantial individual variability in performance (see Fig. 6).
DISCUSSION
The present study examined whether gaze-contingent simulations
of visual impairment (OpenVisSim), presented using a head
mounted display (HMD), are capable of eliciting in normally-
sighted observers the sorts of everyday difficulties experienced by
real glaucoma patients. The results were encouraging. As with real
glaucoma patients, participants were slower to perform everyday
visual-search (VR) and mobility (AR) tasks when experiencing
simulated VFL, and as with real patients these difficulties were
exacerbated when the VFL was inferior. Furthermore, as with real
patients21–23, participants made more head- and eye-movements
when experiencing VFL, to compensate for their restricted field of
view. Taken together, these results suggest that mixed reality (AR/
VR) technologies have interesting potential as a means of
simulating the functional effects of VI in normally-sighted
Fig. 4 Performance on VR search task. a Response time as a function of impairment type (box-and-whisker plots, showing median,
interquartile range, and range). Black dots indicate individual participants. P values relate to Wilcoxon signed-rank tests (i.e., non-parametric
repeated measures t-tests; see body text for statistics). b Scatter plot showing the cumulative distance traveled by each participant’s head and
eyes in a single trial, averaged across all trials. Note the separation between each of the three conditions. c Self-reported difficulty ratings.
Lines indicate individual participants, with those who rated the Inferior condition as more difficult highlighted by purple solid line. Black bars
indicate group-means and 95% confidence intervals (CI95%). d Group-median response times, ±CI95%. These data are the same as those in
panel A, but are here broken down into individual six-trial blocks to assess the consistency of the effect, and possible learning or fatigue.
P.R. Jones et al.
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individuals. This could have wide ranging practical applications, as
detailed below.
Anecdotally, it was also noticeable that, in addition to the
objective changes in performance, many participants reported
feeling anxious when the impairment was active. This was
particularly the case when participants were ascending/descend-
ing the stairs that led to the AR mobility platform. Interestingly,
“climbing stairs” is also a regular source of anxiety for many
people with severe vision loss24, and these ‘psychological’ aspects
of visual impairment can also have a substantial impact on
wellbeing. For example, elevated levels of depression and physical
inactivity are common among the visually impaired25, and in
extreme cases can lead to individuals being afraid to leave their
own homes17. The fact that the simulator was able to elicit these
psychological components was unanticipated but encouraging,
and could be explored more systematically in future.
That inferior deficits are more detrimental for performing some
visually guided actions is consistent with previous self-reports
from real glaucoma patients19,26,27. Unlike with self-report data,
however, the use of VR/AR furthered allowed us to quantify effect
sizes, and explore individual differences. With regard to effect size,
the presence of a severe superior VFL caused average response
times to increase by around 50% (VR Search: 74%; AR Mobility:
54%), versus no impairment. Shifting the scotoma from a superior
to inferior location caused response times to increase by over half
as much again (VR Search: +70%; AR Mobility: +71%). This
indicates that the retinotopic location of an impairment can be
almost as important as the difference between advanced VFL and
having no impairment at all. Regarding individual differences,
Fig. 6 Performance on AR visual. Panels show maze completions times under a Photopic and b Mesopic lighting conditions. Each line
indicates a single participant (same individuals in both conditions).
Fig. 5 Looking behaviors during VR search task. a Eyeball orientation in each condition. Each plot is a 3D histogram showing the estimated
gaze vector, as measured every 8.3 msec throughout the experiment (~500,000 data points per plot, data averaged across eyes, data from all
19 participants included). These histograms show that participants tended to look downwards in the Superior VFL condition, and upwards in
the Inferior VFL condition. b Gaze elevation (in normalized screen units, 0–1) as a function of time for each participant, and the group-mean
value across all participants (bottom-right). The 0.5 point indicates the midline of the head-mounted display screen (central fixation). A value
of 0.75 indicates fixation around the upper quarter of the screen (+14° above the midline). c Response time as a function of gaze-elevation.
Circles represent individual participants (one data-point per participant, per condition). The black curve indicates the best-fitting quadratic
model (weighted sum of squares, fitted using bisquare weights).
P.R. Jones et al.
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there was considerable variability in levels of impairment
exhibited (Fig. 3c). For example, in the VR search task, response
times increased by 52–220% across participants in the Inferior VFL
condition, even though the simulated loss was identical for all.
This supports the intuition that some individuals are better at
coping with same level of sight loss, and shows that this reflects
not just differences in psychology28,29 or lifestyle30, but also
represents genuine differences in capability. The best performing
individuals tended to be those who continued to maintain
relatively normal gaze behaviors even when experiencing VFL, and
it is tempting to speculate whether the present technology could
be adapted to ‘teach’ such adaptive strategies in future.
It would be wrong, on the basis of the present results, to
conclude that inferior VFL is always worse, and it may be that for
other tasks a superior scotoma is more debilitating. For example,
several studies have reported that superior VFL is more
detrimental for particular tasks such as driving26,31–33. One of
the benefits of the present approach is that it can be easily
adapted to explore a range of everyday scenarios. For example,
tasks could be implemented that map onto each of the categories
of behavior defined in the NEI-VFQ-2534 or GQL-1535 (e.g., near-
vision, distance-vision, driving, etc.).
The present technology could also be used to simulate other
VFL profiles, or to explore the needs of a particular patient. For
example, the VF data in the present study was from a single
individual with overlapping (binocular) VFL in each eye. However,
we are also using the same paradigm to explore, for example, how
a purely unilateral deficit effects everyday vision-related tasks36.
The size and location of the simulated visual field loss was
consistent with clinical data, and the use of blur to degrade the
image was consistent with the qualitative reports of patients2.
However, the simulations described in the present work were only
intended as a first-approximation of glaucomatous sight loss. The
simulator could be improved in future by incorporating additional
features, such as spatial distortions and ‘filling-in’ effects: aspects
of glaucoma that are sometimes reported by patients, but which
we currently lack the means to quantify robustly. An ideal
simulator would also take into account the fact that, for many
patients, the extent/quality of their vision loss varies, depend on
their own physiological state or their current viewing conditions
(e.g., level of ambient illumination). Thus, it has been observed
that some glaucoma patients exhibit a greater loss of vision under
home-lighting, than when assessed in a well-lit eye clinic37,38.
Some additional image manipulations are already supported by
the simulator (see Fig. 1c), but were not employed in the present
work, in part due to a lack of appropriate clinical data with which
to constrain them. Some other visual phenomena are difficult to
simulate using current hardware. This is most notably the case
with changes in contrast sensitivity—a common complaint of
many VI patients35, but one that is computationally challenging to
depict accurately, as it requires the simulator to effectively model
an ascending hierarchy of increasing receptive fields, as exist
within the visual system39. It would be helpful in future to develop
algorithmic approximations of contrast sensitivity loss, or specia-
lized hardware capable of quantitatively simulating such deficits in
near-real-time within VR/AR. In order to facilitate further develop-
ment, we have made the complete codebase for our simulator
freely available online (https://github.com/petejonze/
OpenVisSim). Technically minded readers are encouraged to
adapt or modify the code, and can contribute changes to the
online repository. Furthermore, the code is written in a popular
games engine (Unity3D), which means that it is compatible with
all modern hardware (including smartphones), and can be easily
integrated into many existing software packages (e.g., driving
simulators).
This study was intended only as an initial assessment of
feasibility: designed to explore the raw potential of using a head
mounted display (HMD) to deliver digital, gaze-contingent
simulations of visual impairment. A much larger sample, and a
more standardized protocol would be required to formally assess
the accuracy and/or utility of this new technology. It would also be
desirable to explore the usability and acceptability of the
technology in older adults, since the prevalence of eye-disease
increases greatly with age40.
It should also be noted that participants in the present study
experienced an extremely acute onset of vision loss. As a result,
they most likely experienced a ‘positive’ scotoma (a salient
obstruction/alteration in the visual field). This stands in contrast to
many real forms of VI, where vision loss occurs gradually over
many years41, and where, due to a gradual process of adaptation,
patients often report a ‘negative’ scotoma (an imperceptible
absence of information). There was no indication that task
performance or looking behaviors changed over the brief period
of the experiment (see Figs 4d and 5b). However, in future it
would be instructive to explore whether performance, and/or
people’s perceptions of VFL, changed following a longer and
progressive period of simulated sight loss. In this respect, the
possibilities afforded by AR are particularly exciting, as such
devices could foreseeably be worn for days or weeks. It would be
particularly interesting to examine, for example, whether the
human visual system is able to recover from chronically altered
signals, in a similar way as has been reported previously in
audition42, and in vision using prisms43. Likewise, AR could be
used to explore whether prolonged simulated sight-loss leads to
subtle changes in the ‘microstructure’ of eye-movements (e.g., rate
of corrective saccades), as have been shown previously to occur
following glaucoma21,44.
The VI simulator described in the present work combines: (i)
real-time, gaze-contingent image manipulations; (ii) clinical data;
and (iii) stereoscopic presentation via a HMD. Considered in
isolation, these constituent elements are not unique. The core
algorithm for simulating visual field loss in real-time was first
proposed by Geisler and Perry45. The idea of using data from
ophthalmic eye-tests to generate clinically relevant impairments
has been proposed most convincingly by Thompson et al (2017)39.
And many people have developed VR/AR sight-loss simulators46–
49 of varying technical sophistication. To our knowledge, however,
this is the first system to integrate these elements together into a
single, functioning system, and it is the first to be shown capable
of eliciting plausible impairments on the sorts of typical, ‘real
world’ tasks of daily living that patients really value (i.e., rather
than purely perceptual changes in the user’s ability to recognize
words or letters39,46). We anticipate that the present findings
would generalize to other similar system, should any be
developed in future, and that the realism of such systems will
only increase as the hardware and algorithms continue to
develop.
As highlighted in the Introduction, the ability to simulate VI has
many potential applications across science, engineering, and
medicine. In clinical science, an effective simulator could be used
to improve public understanding of visual impairments50: current
low levels10–14 of which are thought to be a key driver behind
current high rates of late diagnosis across many diseases51. A
synthetic testbed could provide novel insights that would be
impractical to obtain from real patients. For example, while it is
already well-established that patients with inferior VFL are more
likely to report difficulties with everyday tasks than their peers
with superior VFL19, in this study we were able to quantify the size
of this effect, and in so doing, show that the difference between a
superior and inferior scotoma can be almost as great as the
difference between a severe superior scotoma and no impairment
at all.
With regards to engineering, sight-loss simulators could be
instrumental in ensuring that products5 and built environments6
are accessible to individuals with reduced vision. This is
increasingly becoming a legal requirement in many countries.
P.R. Jones et al.
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However, regulatory requirements have focused traditionally on
physical disabilities (e.g., ensuring step-free access, and doorways
wide enough to accommodate wheelchairs). This is understand-
able, as the challenges arising from sensory impairments are
complex and hard to codify. What is particularly exciting about the
VR/AR approach proposed in the present work is that it makes
visual accessibility a straightforward, empirical question: architects
and engineers can observe directly what works for users with
reduced vision, and what does not. Often, the necessary changes
may be relatively small, but such changes can nevertheless be
highly meaningful for people with reduced vision. And these may
include purely perceptual factors (e.g., improving lighting, and
increasing the contrast of signage), but also higher levels
considerations, such as making an environment more predictable.
For example, in the VR search task it was observed during piloting
that effects of VFL were further exacerbated if the phone was
allowed to appear in unexpected locations (e.g., inside toilet
bowls, or on the ceiling), or if contextual information were
removed altogether by replacing the target and environment with
randomly textured noise.
In health economics, an effective sight-loss simulator could also
be helpful when determining the financial value of a given
treatment. Thus, one difficulty often faced is how to quantify the
relative cost/benefit of qualitatively distinct interventions—from
chemotherapy for lung cancer, to surgery for glaucoma, or
intravitreal injections for macular degeneration. These health
economic judgments often center on questions such as: how does
the benefit of preserving peripheral vision compare to an
additional eighteen months of life expectancy? The official
position of health-care standards authorities, such as the National
Institute for Health and Care Excellence (NICE) in the UK, is that
such questions should be answered by ordinary, unbiased
members of the general public52. The difficulty, however, is that
the public generally has poor comprehension of what life with a
visual impairment is really like10–14, leading to decisions that may
fail to maximize societal health benefits53. The failure in the past to
simulate vision loss using spectacles or contact lenses has led
some economists to call for precisely the sort of gaze-contingent,
real-time, digital simulator that we describe here4.
More generally, the present work highlights the possibility of
using VR/AR as a new way of evaluating the impact of sight loss on
the sorts of everyday tasks that patients really value. The present
results are promising in that we were able to robustly evidence
changes in both performance and looking behaviors (i.e., eye- and
head-movements), and did so in manner that was safe,
convenient, replicable, and precisely controlled. In this sense,
VR/AR—as has been recently noted recently by others54—can be
seen as the logical extension of traditional ‘performance based’
assessments55 such as the Assessment of Visual Disability Related
to Vision (ADREV)56. However, direct application of VR/AR to
patients will only be appropriate once headsets are developed
that are more comfortable and lightweight, and once they
routinely support effective refractive correction57,58. Once these
technical challenges are solved, however, the potential rewards
are considerable: opening up a powerful new way to objectively
assess the real-world impact of sight loss.
METHODS
Participants
Participants were 23 normally sighted adults aged 18–40 (Median= 26.5)
years. Nineteen performed the main VR search task, while four performed a
secondary AR Visual Mobility task. In all cases, normal vision was confirmed
by letter acuity (equal to or better than 6/12), standard automated
perimetry (“within normal limits” on a Glaucoma Hemifield Test using a
Humphrey Field Analyzer 24-II SITA Fast program; Carl Zeiss Meditec, CA,
USA), and the Wirt Stereo Fly Test (≤80 s). No assessment of far-peripheral
vision was performed, although this could be done in future using wide-
field retinal-imaging or kinetic perimetry. Participants received £15
compensation, and were recruited by adverts placed around City,
University of London.
Ethics
All participants provided informed written consent. All experiments were
conducted in accordance with the declaration of Helsinki, and followed
ethical approval from City, University of London’s School of Health
Sciences (#Opt/PR/16–17/58).
Simulated VFL
To simulate glaucomatous visual field loss (VFL) we created a gaze-
contingent region of variable blur using OpenVisSim (see Fig. 1b and
Supplementary Video 2 for examples; see Supplementary Methods and
Jones and Ometto9 for technical details). Although only intended as a first
approximation, blur is the most consistently reported symptom of
glaucoma patients2, and is prima facie consistent with more sparse
sampling of the scene due to ganglion cells loss and/or dysfunction. The
magnitude and shape of the blur field was determined by clinical data
from a 68-year-old with an established diagnosis of glaucoma (Fig. 2c).
Note that the simulator also supports a variety of other degradation effects
(see Fig. 1c), including as spatial distortions (metamorphopsia), ‘filling-in’
effects, and color vision deficits. These additional effects were not
employed/evaluated in the present work, however, as they are less
commonly reported in glaucoma, and because we generally lack
appropriate quantitative, clinical data with which to constrain them.
Crucially, the location of the VFL on the screen was updated in near-real-
time based on the participants current point-of-gaze, and so remained
static on the observer’s retina, irrespective of eye- or head-movements. The
Inferior VFL was identical in every respect to the superior VFL, except
flipped up-down along the horizontal meridian. The complete source code
for generating the simulated impairments can be found at: https://github.
com/petejonze/OpenVisSim, and is free for non-commercial use.
Primary task: visual search in virtual reality
To assess the impact of the simulated VFL on people’s ability to locate an
object in a cluttered visual scene, 19 participants were asked to find a
mobile phone located around a virtual house (Fig. 2; Supplementary Video
2). Fifteen domestic environments (rooms) were created (see Fig. 2b), and
these were rendered using Unity3D (Unity Technologies ApS, San
Francisco, CA, United States). Environments were viewed stereoscopically
using a virtual reality headset with integrated eye-tracking (FOVE Inc., San
Mateo, CA, United States). On each trial, one of the fifteen virtual rooms
was randomly selected, and the location of the phone, the location of the
participant, and the starting orientation of their head was randomized (NB:
values constrained so that the participant was never directly facing the
target at trial onset). In actuality, participants were seated on a rotating
office chair throughout, but they could turn their body freely (360°) and
were free to move their head and eyes to look around the virtual
environment. Participants pressed a button to indicate when they had
found the phone, and responses were verified as correct only if the
participant’s gaze fell within 45° of the target (NB: This 45° criterion was
intended only to filter out occasional ‘finger press’ errors, and participants
were monitored throughout to ensure they were performing the task
correctly). The primary outcome measure was response time. Eye and head
movements were also tracked using the headsets near-infrared and
gyroscopic sensors.
Participants completed three blocks of 30 trials (90 trials total; ~45min,
including breaks). Each block tested a single condition (No VFL, Superior
VFL, Inferior VFL). The order of conditions was randomized between
participants. Before the first block, participants were shown the target
phone, and completed 10 practice trials (No VFL).
Secondary task: visual mobility using augmented reality
Glaucoma is also associated with reduced mobility and increased risk of
falls. To confirm that any effects generalize beyond the main virtual-reality
search task, we also asked four new participants to perform a real-world
mobility task, in which they navigated the maze shown in Fig. 3 (a physical
environment constructed previously to evaluate the efficacy of gene
therapies for inherited eye-disease59). The simulated VFL conditions were
identical to those in the primary search task: the only difference being that
the raw input to each eye was not computer generated, but instead
P.R. Jones et al.
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provided by a pair of forward-facing stereoscopic cameras (Augmented
Reality). Again, the hypothesis was that performance would be worst
(slowest) when the VFL was inferior.
Note that fewer participants (N= 4) took part in this task than in the
main VR experiment (N= 19). This reflects the much greater costs—both in
terms of time and money—associated with ‘real-world’ testing, as well as
the fact that the results were only intended to confirm and extend the
results from the primary experiment. Participants completed the task twice
under photopic conditions equivalent to ordinary office lighting (256 lux),
and twice under mesopic conditions (4 lux; UK nighttime pedestrian
lighting standard).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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